Insiders who reported open-market trades in the last 12 months at the companies Richard Nolan Townsend files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Narinder Pal Bhalla - $99K in LXEO purchases and sales in the last 12 months
Jose Manuel Otero - $60K in LXEO purchases and sales in the last 12 months
Louis Edward Tamayo - $41K in LXEO purchases and sales in the last 12 months
Eric Adler - $6K in LXEO purchases and sales in the last 12 months
Jenny Robertson - $5K in LXEO purchases and sales in the last 12 months
Tai Sandi See - $4K in LXEO purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Richard Nolan Townsend is a corporate insider, tracked as Chief Executive Officer, Director of Lexeo Therapeutics, Inc. (LXEO). InsiderAlpha holds 15 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Richard Nolan Townsend submitted recently?
2 primary Form 4 filings in the last 90 days, covering 1 company.
Has Richard Nolan Townsend been buying or selling stock?
Recorded transactions: 0 open-market purchases and 12 open-market sales ($741K) across all tracked filings.
Richard Nolan Townsend is Chief Executive Officer, Director of Lexeo Therapeutics, Inc. (LXEO). 15 SEC Form 4 filings on record going back to 2024, most recently on 28 September 2026. Most recent open-market trade: sold $17K of LXEO on 19 August 2026. Lifetime open-market sales: $741K.
Recent transactions
20
The latest 20 SEC Form 4 transactions reported by Richard Nolan Townsend.
InsiderAlpha's records for Richard Nolan Townsend go back to 2024: 15 primary Form 4 filings, an average of 5.0 per year. 10 recorded transactions carry a Rule 10b5-1 plan flag. This identifies the marked transactions as reported under a trading plan; it does not establish the plan status of unmarked transactions.
